The OlympiA trial also demonstrated that adjuvant olaparib significantly improves invasive disease-free and overall survival in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer [28,29]. This evidence concerns the gene BRCA1 and breast carcinoma.